Indivior (NASDAQ:INDV) Director Stuart Kingsley Purchases 940 Shares

Indivior PLC (NASDAQ:INDV) Director Stuart Kingsley purchased 940 shares of the business’s stock in a transaction dated Friday, March 6th. The shares were purchased at an average price of $31.86 per share, with a total value of $29,948.40. Following the acquisition, the director directly owned 5,582 shares in the company, valued at approximately $177,842.52. The trade was a 20.25% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Indivior Price Performance

Shares of INDV stock traded up $1.74 during trading hours on Wednesday, hitting $35.08. The company had a trading volume of 815,349 shares, compared to its average volume of 1,916,924. The stock has a market capitalization of $4.39 billion, a PE ratio of 21.39 and a beta of 0.83. Indivior PLC has a fifty-two week low of $8.64 and a fifty-two week high of $38.00. The company’s fifty day moving average is $33.99 and its 200 day moving average is $30.51.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.17. Indivior had a net margin of 16.85% and a negative return on equity of 148.76%. The firm had revenue of $358.00 million during the quarter, compared to analysts’ expectations of $305.62 million. Equities analysts forecast that Indivior PLC will post 1.22 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Morgan Stanley reissued an “overweight” rating and issued a $36.00 target price on shares of Indivior in a report on Wednesday, December 3rd. Northland Securities set a $50.00 price target on shares of Indivior in a research report on Tuesday, January 20th. HC Wainwright increased their price objective on shares of Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Zacks Research cut Indivior from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 13th. Finally, Weiss Ratings raised shares of Indivior from a “hold (c)” rating to a “buy (b-)” rating in a research note on Monday, March 2nd. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, Indivior has an average rating of “Moderate Buy” and an average target price of $39.33.

Institutional Investors Weigh In On Indivior

A number of hedge funds have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd grew its position in Indivior by 72.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after buying an additional 460 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Indivior during the 4th quarter valued at about $344,000. Invesco Ltd. increased its holdings in shares of Indivior by 274.6% in the fourth quarter. Invesco Ltd. now owns 286,689 shares of the company’s stock valued at $10,286,000 after buying an additional 210,150 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in Indivior during the 4th quarter worth about $274,000. Finally, EP Wealth Advisors LLC purchased a new position in shares of Indivior in the fourth quarter worth approximately $481,000. 60.33% of the stock is currently owned by institutional investors.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.